Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7471 to 7485 of 7707 results

  1. EndoPredict gene expression profiling assay for assessing risk of breast cancer recurrence (MIB44)

    This advice has been updated and replaced by NICE diagnostics guidance 34.

  2. Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for early triple negative breast cancer [ID6200]

    In development [GID-TA11165] Expected publication date: TBC

  3. Unilateral MRI-guided focused ultrasound thalamotomy for moderate to severe tremor in Parkinson's disease (IPG606)

    This guidance has been updated and replaced by NICE interventional procedures guidance 796.

  4. myCOPD for managing chronic obstructive pulmonary disease (MTG68)

    This guidance has been updated and replaced by NICE health technology evaluation 19, which covers using myCOPD for self-management of chronic obstructure pulmonary disease (COPD), and NICE health technology evaluation 18, which covers using myCOPD for pulmonary rehabilitation.

  5. Lenus COPD Support Service for remotely managing chronic obstructive pulmonary disease (MIB300)

    This guidance has been updated and replaced by NICE health technology evaluation 19.

  6. Pembrolizumab for adjuvant treatment of locally advanced cutaneous squamous cell carcinoma after surgery and radiotherapy ID 6473

    In development [GID-TA11582] Expected publication date: TBC

  7. Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (TA529)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1021.

  8. Ruxolitinib for disease-related splenomegaly or symptoms in adults with myelofibrosis (TA289)

    This guidance has been updated and replaced by NICE technology appraisal guidance 386.

  9. Guidance on the use of long‑acting insulin analogues for the treatment of diabetes – insulin glargine (TA53)

    This guidance has been replaced by NICE guideline NG17.

  10. Farco-fill Protect for indwelling urinary catheterisation (MIB121)

    July 2021: NICE has withdrawn the medtech innovation briefing (MIB) on Farco-fill Protect for indwelling urinary catheterisation because the product has been withdrawn from the UK market.

  11. Master healthcare decision-making with LSE and NICE

    Lead with confidence through our Executive MSc in Healthcare Decision-Making.

  12. More people are benefitting from NICE-recommended statins to reduce heart attacks and strokes

    Around 5.3 million people in England were given a NICE-recommended statin or ezetimibe by their GP to help reduce their cholesterol during 2023/24, the largest number on record and almost 900,000 more than in 2022/23.

  13. Introducing CHEERS-AI: improving health economic evaluation reporting for AI technologies

    Our contribution to world-leading research.

  14. Your voice is needed – my experience as a NICE committee member

    Dr Raja discusses the vital role frontline NHS colleagues have on our independent committees, and how you can get involved.

  15. People with a rare form of blood cancer are set to benefit after NICE recommends new targeted therapy

    Hundreds of people with multiple myeloma could receive a new, targeted treatment recommended for use within the Cancer Drugs Fund today (Tuesday, 29 October).